Johnson & Johnson says its single-shot COVID-19 vaccine generates strong, persistent activity against the Delta and other highly prevalent variants.
Data showed the durability of the immune response lasted through at least eight months, the US-based healthcare company said on Thursday, adding its vaccine was 85 per cent effective and could also help prevent hospitalisation and death.
“Current data for the eight months studied so far shows that the single-shot Johnson & Johnson COVID-19 vaccine generates a strong neutralising antibody response that does not wane; rather, we observe an improvement over time,” Mathai Mammen, head of research & development at J&J’s drugs business, said.
The COVID-19 vaccine elicited neutralising antibody activity against the Delta variant, first identified in India, at an even higher level than what was observed for the Beta variant, which was first detected in South Africa, the company said.
J&J has submitted data as a preprint to the website bioRxiv ahead of peer review.